Daily, Health IT, Startups

Following $110M fundraise, Tempus reveals mobile app to give doctors access to clinical data

Called Tempus Labs, the Chicago startup's new tool is currently available and allows physicians to securely access patient information at the point of care.

After announcing a $110 million Series E funding round a few weeks ago, Chicago-based Tempus, a company focused on the collection and analysis of molecular and clinical data, has launched a new mobile app that lets physicians securely access clinical and genomic data at the point of care.

Called Tempus Labs, the tool is currently available on the App Store and Google Play. It was previously piloted with doctors across the nation.

It is available for physicians who order one of the Tempus CLIA/CAP validated assays: xT, which analyzes 595 genes; xO, which analyzes 1714 genes; and xE, which analyzes the whole exome.

Through the mobile app, doctors can view a patient’s clinical history, potential therapy options and clinical trials for which they are eligible.

“Our intention is to make the Tempus platform accessible to physicians wherever they are, immediately at their fingertips,” Tempus COO Ryan Fukushima said via email. “Our team designed it based on conversations with physicians, incorporating their feedback about how their busy clinic schedules can make working at a computer and regularly accessing the Tempus platform challenging.”

The ultimate goal of Tempus Labs is that it will enable doctors to access information that can help them make better treatment decisions for patients, Fukushima added.

In addition to the mobile app, the company announced its $110 million funding gain in late August. The Series E round included investments from Baillie Gifford, funds and accounts managed by T. Rowe Price, Revolution Growth, New Enterprise Associates and other existing investors.

The company said it plans to use the money to grow its operations and expand into new therapeutic areas like cardiovascular disease or neurological disorders.

“A number of our clinical partners have asked us to extend our capabilities into additional disease areas, and now that our platform is operating at scale, we believe we can do that without taking focus away from our work in oncology,” Fukushima said.

Tempus was founded by Groupon co-founder and chairman Eric Lefkofsky. He currently serves as CEO of the company, which is creating a library of molecular and clinical data as well as an operating system to make the information accessible.

Last December, the Chicago startup also unveiled an operating system called Tempus O, which is designed to structure, cleanse, and annotate clinical data.

Photo: ipopba, Getty Images

Shares0
Shares0